Private biotech 2004- the numbers
Article Abstract:
An analysis of the financial performance of the privately held biotech sector in 2004 in the US and Europe is presented as around 85% of all healthcare and healthcare-related biotech companies are privately owned. The area of focus for examining during the research includes employment, research and development, raising finance, generating revenue till becoming a public company.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Where the money is
Article Abstract:
The US capital markets' role in making the US biotech tech industry as one of the worlds largest in both market value and product sales is examined. The future of the US capital market, its competitors around the world and fate of the global biotech industry are discussed.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: The beginning of the end game. Only for the brave. Living on the edge
- Abstracts: Shift toward early-stage deals favors bioteochs. Public biotech 2006- the numbers
- Abstracts: Power to the people. A fare job. Retail therapy
- Abstracts: Cross-decking, other moves permit more missions with same ships. Adm. Nathman says perhaps just 40 to 50 LCSs required
- Abstracts: VAT update. VAT update: Carousel fraud- the end of the road